Tubulin binding potentially clears up Bortezomib and Carfilzomib differential neurotoxic effect
Abstract Proteasome inhibitors (PIs) represent the gold standard in the treatment of multiple myeloma. Among PIs, Bortezomib (BTZ) is frequently used as first line therapy, but peripheral neuropathy (PN), occurring approximately in 50% of patients, impairs their life, representing a dose-limiting to...
Enregistré dans:
| Auteurs principaux: | , , , , , , , , |
|---|---|
| Format: | article |
| Langue: | EN |
| Publié: |
Nature Portfolio
2021
|
| Sujets: | |
| Accès en ligne: | https://doaj.org/article/5bb52f7cbfd047d0957809e366036543 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|